Non-inferiority trials: why oncologists must remain wary

Lancet Oncol. 2015 Apr;16(4):364-6. doi: 10.1016/S1470-2045(15)70129-4.

Authors

Mauricio Burotto¹, Vinay Prasad¹, Tito Fojo²

Affiliations

¹ Medical Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
² Medical Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: fojot@mail.nih.gov.

PMID: 25846084
DOI: 10.1016/S1470-2045(15)70129-4

No abstract available

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
Drug Approval
Humans
Neoplasms / drug therapy*
Neoplasms / pathology

Substances

Antineoplastic Agents